Targeting metastatic upper gastrointestinal adenocarcinomas

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

344

HTML

4900

Figures (1-3)

194

Tables (1-2)

183

Sum=5621

Mar 10, 2011 (publication date) through Jul 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Mar 10, 2011; 2(3): 135-149
Published online Mar 10, 2011. doi: 10.5306/wjco.v2.i3.135

Table 1 Human epidermal growth factor receptor family inhibitors in upper gastrointestinal malignancies

Drug	Mechanism of action	Applicable tumor site(s)
Cetuximab	Intravenous IgG1 monoclonal antibody inhibiting the extracellular domain of EGFR thereby preventing receptor activation	Gastric
		Biliary tract
		Pancreas
Erlotinib	Oral intracellular small molecule selective EGFR TKI	Biliary tract
Erlotinib	Oral intracellular small molecule selective EGFR TKI	Pancreas
Trastuzumab	Intravenous recombinant humanized anti-HER2 monoclonal antibody directed against the HER-2 extracellular domain	Gastric
Lapatinib	Oral TKI targeting EGFR and HER-2	Gastric

EGFR: Endothelial growth factor receptor; TKI: Tyrosine kinase inhibitor; HER: Human epidermal growth factor receptor.

Citation: Spratlin JL, Chu Q, Koski S, King K, Mulder K. Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011; 2(3): 135-149
URL: https://www.wjgnet.com/2218-4333/full/v2/i3/135.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i3.135